European Medicines Agency decision
P/0149/2018

of 17 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for
ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M07) in accordance with Regulation (EC)

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of

Only the English text is authentic.
European Medicines Agency decision
P/0149/2018

of 17 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for
ceftazidime / avibactam (Zavicefta), (EMEA-001313-PIP01-12-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency’s decision P/0083/2013 issued on 26 April 2013, the decision P/0133/2014 issued on 10 June 2014, the decision P/0052/2015 issued on 6 March 2015, the decision P/0251/2015 issued on 30 October 2015, the decision P/0062/2017 issued on 17 March 2017 and the decision P/0314/2017 issued on 31 October 2017,

Having regard to the application submitted by Pfizer Limited on 5 February 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 April 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for ceftazidime / avibactam (Zavicefta), powder for concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ – Sandwich, United Kingdom.
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001313-PIP01-12-M07

Scope of the application

Active substance(s):
Ceftazidime / avibactam

Invented name:
Zavicefta

Condition(s):
Treatment of intra-abdominal infections
Treatment of urinary tract infections
Treatment of pneumonia
Treatment of infections due to aerobic Gram-negative organisms

Authorised indication(s):
See Annex II

Pharmaceutical form(s):
Powder for concentrate for solution for infusion

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Pfizer Limited

Information about the authorised medicinal product:
See Annex II
**Basis for opinion**

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Limited submitted to the European Medicines Agency on 5 February 2018 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency’s decision P/0083/2013 issued on 26 April 2013, the decision P/0133/2014 issued on 10 June 2014, the decision P/0052/2015 issued on 6 March 2015, the decision P/0251/2015 issued on 30 October 2015, the decision P/0062/2017 issued on 17 March 2017 and the decision P/0314/2017 issued on 31 October 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 February 2018.

**Scope of the modification**

Some measures and timelines of the Paediatric Investigation Plan have been modified.

**Opinion**

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexe s and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. **Waiver**

Not applicable

2. **Paediatric investigation plan**

2.1. **Condition**

Treatment of intra-abdominal infections

2.1.1. **Indication(s) targeted by the PIP**

Treatment of complicated intra-abdominal infections (cIAIs)

2.1.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years of age

2.1.3. **Pharmaceutical form(s)**

Powder for concentrate for solution for infusion

2.1.4. **Measures**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
</table>
| Quality-related studies     | 1                  | **Study 1**
|                             |                    | Development of an age-appropriate powder for concentrate for solution for infusion of ceftazidime and avibactam in a single vial |
| Non-clinical studies        | 1                  | **Study 2**
|                             |                    | 14-day repeat dose toxicity study in juvenile rats                           |
| Clinical studies            | 3                  | **Study 3 (D4280C00014)**
|                             |                    | Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from 3 months to less than 18 years of age with suspected or confirmed bacterial infection and receiving other systemic antibiotic therapy |
|                             |                    | **Study 4 (D4280C00015)**
|                             |                    | Single-blind, randomised, active controlled, trial to evaluate safety, tolerability and efficacy of ceftazidime and avibactam in children from 3 months to less than 18 years of age with complicated intra-abdominal infections (cIAIs) |
2.2. Condition

Treatment of urinary tract infections

2.2.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infections (cUTIs)

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.2.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
</table>
| Quality-related studies     | 1                  | Study 1<br>Development of an age-appropriate powder for concentrate for solution for infusion of ceftazidime and avibactam in a single vial<br>
|                             |                    | Same study as for condition ‘treatment of intra-abdominal infections’      |
| Non-clinical studies        | 1                  | Study 2<br>14-day repeat dose toxicity study in juvenile rats<br>
|                             |                    | Same study as for condition ‘treatment of intra-abdominal infections’      |

**Study 6 (D4280C00017)**

Open-label, single and multiple dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from birth to less than 3 months of age with suspected or confirmed infections due to aerobic Gram-negative pathogens requiring intravenous antibiotic treatment
Clinical studies | 3 | **Study 3 (D4280C00014)**
Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from 3 months to less than 18 years of age with suspected or confirmed bacterial infection and receiving other systemic antibiotic therapy

*Same study as for condition ‘treatment of intra-abdominal infections’*

**Study 5 (D4280C00016)**
Single-blind, randomised, active controlled, trial to evaluate safety, tolerability and efficacy of ceftazidime and avibactam in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTI)

**Study 6 (D4280C00017)**
Open-label, single and multiple dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from birth to less than 3 months of age with suspected or confirmed infections due to Gram-negative pathogens requiring intravenous antibiotic treatment

*Same study as for condition ‘treatment of intra-abdominal infections’*

**2.3. Condition**

Treatment of pneumonia

**2.3.1. Indication(s) targeted by the PIP**

Treatment of nosocomial pneumonia

**2.3.2. Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years of age

**2.3.3. Pharmaceutical form(s)**

Powder for concentrate for solution for infusion
### 2.3.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>1</td>
<td><strong>Study 1</strong>&lt;br&gt;Development of an age-appropriate powder for concentrate for solution for infusion of ceftazidime and avibactam in a single vial&lt;br&gt;Same study as for condition ‘treatment of intra-abdominal infections’</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>1</td>
<td><strong>Study 2</strong>&lt;br&gt;14-day repeat dose toxicity study in juvenile rats&lt;br&gt;Same study as for condition ‘treatment of intra-abdominal infections’</td>
</tr>
<tr>
<td>Clinical studies</td>
<td>3</td>
<td><strong>Study 3 (D4280C00014)</strong>&lt;br&gt;Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from 3 months to less than 18 years of age with suspected or confirmed bacterial infection and receiving other systemic antibiotic therapy&lt;br&gt;Same study as for condition ‘treatment of intra-abdominal infections’<strong>&lt;br&gt;<strong>Study 6 (D4280C00017)</strong>&lt;br&gt;Open-label, single and multiple dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from birth to less than 3 months of age with suspected or confirmed infections due to Gram-negative pathogens requiring intravenous antibiotic treatment&lt;br&gt;Same study as for condition ‘treatment of intra-abdominal infections’</strong>&lt;br&gt;<strong>Study 8 (D4280C00028)</strong>&lt;br&gt;Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime (CAZ) and avibactam (AVI) in children from 3 months to less than 18 years of age with suspected or confirmed bacterial nosocomial pneumonia (including ventilator associated pneumonia) and receiving other systemic antibiotic therapy</td>
</tr>
</tbody>
</table>
Extrapolation, modelling and simulation studies | 2 | **Study 7 (CAZ-MS-PED-02)**
Population pharmacokinetic (PK) modelling and PK/pharmacodynamic (PD) probability of target attainment (PTA) analysis for dose selection across paediatric age groups for patients with nosocomial pneumonia or with infections caused by Gram-negative bacteria

**Study 9 (CAZ-MS-PED-04)**
Extrapolation study of the clinical efficacy and safety data for ceftazidime-avibactam (CAZ-AVI) from the adult Phase III and paediatric programmes to paediatrics patients with nosocomial pneumonia or with infections caused by Gram-negative bacteria

| Other studies | 0 | Not applicable |
| Other measures | 0 | Not applicable |

### 2.4. Condition

Treatment of Gram-negative bacterial infections

#### 2.4.1. Indication(s) targeted by the PIP

Treatment of infections due to aerobic Gram-negative pathogens in patients with limited treatment options

#### 2.4.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

#### 2.4.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

#### 2.4.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
</table>
| Quality-related studies   | 1                  | **Study 1**
Development of an age-appropriate powder for concentrate for solution for infusion of ceftazidime and avibactam in a single vial

*Same study as for condition ‘treatment of intra-abdominal infections’*
| Non-clinical studies | 1 | **Study 2**  
14-day repeat dose toxicity study in juvenile rats  
Same study as for condition ‘treatment of intra-abdominal infections’ |
|---------------------|---|------------------------------------------------|
| Clinical studies    | 2 | **Study 3 (D4280C00014)**  
Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from 3 months to less than 18 years of age with suspected or confirmed bacterial infection and receiving other systemic antibiotic therapy  
Same study as for condition ‘treatment of intra-abdominal infections’  
**Study 6 (D4280C00017)**  
Open-label, single and multiple dose trial to evaluate pharmacokinetics, safety and tolerability of ceftazidime and avibactam in children from birth to less than 3 months of age with suspected or confirmed infections due to Gram-negative pathogens requiring intravenous antibiotic treatment  
Same study as for condition ‘treatment of intra-abdominal infections’ |
| Extrapolation, modelling and simulation studies | 2 | **Study 7 (CAZ-MS-PED-02)**  
Population pharmacokinetic (PK) modelling and PK/pharmacodynamic (PD) probability of target attainment (PTA) analysis for dose selection across paediatric age groups for patients with nosocomial pneumonia or with infections caused by Gram-negative bacteria  
Same study as for condition ‘treatment of pneumonia’  
**Study 9 (CAZ-MS-PED-04)**  
Extrapolation study of the clinical efficacy and safety data for ceftazidime-avibactam (CAZ-AVI) from the adult Phase III and paediatric programmes to paediatrics patients with nosocomial pneumonia or with infections caused by Gram-negative bacteria  
Same study as for condition ‘treatment of pneumonia’ |
| Other studies       | 0 | Not applicable |
| Other measures      | 0 | Not applicable |
3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety/efficacy issues in relation to paediatric use:</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By September 2022</td>
</tr>
<tr>
<td>Deferral for one or more measures contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Annex II

Information about the authorised medicinal product
**Condition(s) and authorised indication(s):**

1. Treatment of intra-abdominal infections
   Authorised indication(s):
   - Treatment of complicated intra-abdominal infections (cIAI) in adults

1. Treatment of urinary tract infections
   Authorised indication(s):
   - Treatment of complicated urinary tract infection (cUTI), including pyelonephritis, in adults

2. Treatment of pneumonia
   Authorised indication(s):
   - Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults

3. Treatment of infections due to aerobic Gram-negative organisms
   Authorised indication(s):
   - Infections due to aerobic Gram-negative organisms in adult patients with limited treatment options

**Authorised pharmaceutical form(s):**

Powder for concentrate for solution for infusion (powder for concentrate)

**Authorised route(s) of administration:**

Intravenous use